Mirtazapine for Nausea Management

Introduction to Mirtazapine

Mirtazapine is an effective antiemetic agent for managing nausea, particularly refractory nausea, and should be considered as a treatment option at doses of 7.5-30 mg daily, according to the American Gastroenterological Association and Clinical Gastroenterology and Hepatology 1, 2

The American Gastroenterological Association guidelines specifically list mirtazapine as a treatment option for refractory gastroparesis symptoms at doses of 7.5-30 mg/day 2
Mirtazapine improved refractory nausea and vomiting in a cohort of patients with gastroparesis, with particular efficacy for early satiation and dyspeptic symptoms 1
The American Heart Association's 2024 palliative care guidelines recognize mirtazapine as useful for appetite stimulation in patients with end-stage cardiovascular disease, particularly when concomitant sleep difficulties or mood disorders exist 3

Beyond nausea control, mirtazapine simultaneously addresses appetite loss, insomnia, and mood disorders—common comorbidities in patients with chronic nausea 3, 1
Mirtazapine can be safely combined with other antiemetics targeting different mechanisms, such as metoclopramide or NK-1 antagonists 1, 2
The American Heart Association specifically endorses mirtazapine's use in end-stage cardiovascular disease patients, noting it does not significantly prolong QT intervals, making it safer in patients with cardiac disease 3

Unlike some antiemetics, mirtazapine does not significantly prolong QT intervals, making it safer in patients with cardiac disease 3